Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.8M |
| Cost of revenue | $0 | $0 | $0 | $2.1M | $357.0K | $431.0K | $440.0K | $3.5M |
| Gross profit | $0 | $0 | $0 | −$2.1M | −$357.0K | −$431.0K | −$440.0K | −$1.7M |
| Gross margin | — | — | — | — | — | — | — | -95.0% |
| R&D | $19.1M | $15.0M | $22.0M | $31.5M | $41.4M | $50.2M | $42.7M | $22.3M |
| Operating income | −$23.7M | −$19.5M | −$33.6M | −$48.2M | −$62.3M | −$87.2M | $75.0M | −$73.0M |
| EBITDA | −$24.5M | −$20.2M | −$32.6M | −$29.0M | −$60.6M | −$86.7M | $75.4M | −$53.4M |
| Net income | −$22.7M | −$19.0M | −$52.9M | −$34.4M | −$76.4M | −$92.4M | −$154.4M | −$63.0M |
| Net margin | — | — | — | — | — | — | — | -3531.2% |
| EPS (diluted) | -1.26 | -1.06 | -2.12 | -1.16 | -1.75 | -1.56 | -2.42 | -0.57 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $371M | $0.90 | $0.90–$0.90 | 1 |
| 2027 | $727M | $2.20 | $2.20–$2.20 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds GMDA.
No tracked institution reports a position in GMDA as of their last filing.
No one on the platform has traded GMDA yet.
| $4M |
| — |
| HILSHillstream BioPharma, Inc. | $0.24 | +5.66% | $4M | — |
| IDRAIdera Pharmaceuticals, Inc. | $0.42 | -23.04% | $0 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.